Overview

Olmesartan Medoxomil and Diabetic Nephropathy

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy

Phase:

Phase 3

Details

Lead Sponsor:

Sankyo Pharma Gmbh

Treatments:

Losartan
Olmesartan
Olmesartan Medoxomil